Lymphocyte activation gene-3 (LAG-3), also known as CD223 or FDC protein, is a novel immune checkpoint receptor expressed on CD4+, CD8+Tcells and natural killer (NK) cells and plays an important role in regulating the immune response against tumor antigens and autoantigens. The binding of LAG-3 to its functional ligand, the MHCII complex, results in cytokine production, activated T cells proliferation, and inhibition of TCR signaling. Therapeutics designed to exploit the LAG-3/MHCII binding have shown encouraging results as a potential treatment for many human diseases, including autoimmunity and cancer.
To provide a screening assay for identifying small and large molecule LAG-3 and MHCII binding interaction blockage inhibitors, with the goal of eventually studying immune responses to aid in the discovery of novel immunotherapies to combat cancer.
LAG3-MHCII
Human LAG3, human MHCII
LAG3: Lymphocyte activation gene 3 protein, CD223, FDC
MHCII: HLA-DRA, MHC class II antigen DRA, HLA class II histocompatibility antigen, DR alpha chain
Binding interaction between LAG3 and MHCII
HTRF
| Compounds | IC50 (nM) |
|---|---|
| Ieramilimab | 2.8 |
Malvern, PA, USA
More information can be found on our website Immune Checkpoint Assays
Reference compound inhibition of LAG3-MHCII binding interaction
